Astellas Pharma Inc.: U.S. FDA Approves Expanded Label for Astellas' IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today ...
Biocompatible nanoadhesive offers hope for safer corneal transplants, reducing inflammation and infection risks
A research team from the Eye & ENT Hospital of Fudan University, China, has developed a novel biocompatible nanoadhesive for ...
Healio10d
VIDEO: Multimodal imaging essential for geographic atrophy management
In this Healio Video Perspective from Retina 2025, Roger A. Goldberg, MD, MBA, discusses the role of multimodal imaging in geographic atrophy in the era of complement inhibitors.Imaging confirms the ...
Seeking Alpha14d
Opthea: Small Australian Company Aiming To Upend The Wet AMD Market
In wet AMD, certain mutations, age, environmental and other factors cause choroidal neovascularization, where abnormal, leaky blood vessels form. The leakage causes fluid accumulation, which ...
Active Biotech AB: Active Biotech's patent for laquinimod in eye disorders granted in the US
Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent Office (USPTO) has granted Active Biotech's US patent application 17/939,109 for laquinimod in eye disorders. "We ...
C&EN22d
177 Lu-Labeled Heterodimeric Agent with High Stability Targeting Neovascularization for Tumor Radioligand Therapy
Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China Hubei Province Key Laboratory of Molecular Imaging, Wuhan ...
C&EN22d
Reactive Oxygen Species-Responsive Gel-Based Microneedle Patches with Antimicrobial and Immunomodulating Properties for Oral Mucosa Disease Treatment
Luzhou Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, The Affiliated Stomatological Hospital, Southwest Medical University, Luzhou 646000, China ...
BioWorld28d
CREB inhibitor successfully prevents corneal neovascularization
Corneal neovascularization (CNV) occurs when abnormal blood vessels grow into the cornea in response to ischemic or hypoxic conditions caused by infections, inflammation or chemical injuries. CREB ...
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...